Anti-diabetic Medications (Exam 1) Flashcards
MOA of sulfonylureas
increase peripheral glucose utilization
decrease hepatic gluconeogenesis
increase number and sensitivity of insulin receptors
sulfonylureas are associated with
weight gain
functions of amylin
suppresses appetite
inhibits glucagon release
slows gastric emptying
which decreases plasma glucose
2nd gen sulfonylureas should be used with caution in patients with
cardiovascular disease
elderly patients
glyburide
hepatic metabolism into products with very low hypoglycemic activity
re-titration required when switching from glyburide to other sulfonylureas
glyburide use is restricted for
hepatic impairment and renal insufficiency patients
glipizide
shortest half life (2-4 hrs)
MDD cannot exceed 40 mg
90% glipizide metabolized in liver, rest excreted unchanged in urine
Glucotrol XL
24 hour action ER glipizide
when should glipizide be ingested?
30 minutes before breakfast to minimize postprandial hyperglycemia
glipizide is contraindicated in patients with
significant hepatic impairment
glipizide is preferred over glyburide in ____________ due to its
elderly and renal impaired patients
lower potency and shorter duration of action
glimepiride
once daily use alone or combined with insulin
half life: 5-9 hours
completely metabolized by liver
glimepiride achieves ____________________________ of any sulfonylurea compound
blood glucose lowering with the lowest dosage
Repaglinide
non-sulfonylurea insulin secretagogue with hypoglycemic activity
dosed alone or with metformin
repaglinide can be given to individuals with _____________ allergy because it has no __________________
sulfur or sulfonylurea
sulfur in its structure
MOA of repaglinide
acts on beta cells to release insulin by regulating K efflux through K channels
how is repaglinide similar to sulfonylureas
two common binding sites, one unique binding sites
Repaglinide is cleared by ___________ with a plasma half life of _____________
hepatic CYP3A4
1 hour
what metabolized repaglinide?
where are the metabolites excreted?
CYP3A4 and CYP2C8
the bile
repaglinide is indicated for use in
controlling postprandial glucose excursions
when on repaglinide, if a meal is delayed/skipped or contains low carbs,
hypoglycemia could be at risk
drugs usable in renally impaired and elderly
repgalinide
nateglinide
glipizide
nateglinide MOA
stimulates rapid and transient release of insulin from B cells through closure of ATP sensitive K channel
Nateglinide works better when
combined with non-secretagogue oral agents (metformin)
Nateglinide is metabolized in the liver by
CYP2C9 and CYP3A4
main adverse effect of nateglinide
hypoglycemia
when is nateglinide taken?
before a meal and reduces the postprandial rise in blood glucose levels
when is nateglinide absorbed?
peak concentration?
duration of action?
half life?
20 minutes after oral administration
less than 1 hour
4 hours
1 hour
metformin MOA
inhibits mitochondrial chain complex 1 which decreases ATP levels and activates AMPK
inhibits hepatic gluconeogenesis and opposes the action of glucagon
how does metformin use lead to increase in lactic acid?
it inhibits glycerol 3 phosphate dehydrogenase which stimulates conversion of pyruvate to lactate
what transcription factors does metformin activate using AMPK pathway
what happens when these factors are activated?
CBP (CREB-binding protein)
CRTC2 (CREB-regulated transcription coactivator 2)
decreased gluconeogenic gene expression
what is first line of therapy for T2DM?
metformin
metabolism of metformin
half life - 1.5-3hrs
not bound to plasma proteins
excreted by the kidneys as the active compound
metformin blocks ____________ and impairs the hepatic _________________
gluconeogenesis
lactic acid metabolism
in renal insufficiency, the biguanide _____________ and thereby increases the risk of _______________
accumulates
lactic acidosis
metformin is contraindicated if the
eGFR is less than 30ml/min
Metformin does not increase _____________ or provoke _______________
body weight
hypoglycemia
metformin can be used in combination with
insulin secretagogues or thiazolidinediones
metformin decreases the risk of
macrovascular and microvascular disease
which group of people does metformin prevent new onset T2DM in?
middle aged obese persons with impaired glucose tolerance and fasting hyperglycemia
toxic effects of metformin
GI upsets
diarrhea
how does metformin cause vitamin B12 deficiency?
it interferes with calcium dependent absorption of vitamin B 12 intrinsic factor complex
after many years of use
Metaglip
metformin and glipizide
Kombiglyze
saxagliptin and metformin
avandaryl
rosiglitazone and glimepiride
actoplus met
pioglitazone and metformin
glucovance
metformin and glyburide
avandamet
rosiglitazone and metformin
duetact
pioglitazone and glimepiride
janumet
sitagliptin and metformin
prandimet
repaglinide and metformin
jentadueto
metformin and linagliptin
synjardy
empagliflozin and metformin
xigduo
dapagliflozin and metformin
ivonkamet
canagliflozin and metformin
3 isoforms of intracellular nuclear transcription factors of thiazolidinediones
alpha (PPARa)
gamma (PPARy)
beta/delta (PPARb/d)
PPARy is expressed on
liver, adipose tissue and muscle
by activating PPARy, TZDs promote
fatty acid uptake and storage in adipose tissue rather than skeletal muscle and liver
when PPAR alpha is activated
reduction in TG level
involved in regulation of energy homeostasis
when PPAR gamma is activated
insulin sensitization
enhances glucose metabolism
when PPAR b/d is activated
enhances fatty acid metabolism
humoral stimulants of insulin release
glucose
mannose
leucine
arginine
AA
fatty acids
hormonal stimulants of insulin release
glucagon
GLP-1
glucose dependent insulinotropic polypeptide
cholecystokinin
gastrin
neural stimulants of insulin release
beta adrenergic stimulation
vagal stimulation
drug stimulants of insulin release
sulfonylureas
meglinitide
nateglinide
isoproterenol
acetylcholine
hormonal inhibitors of insulin release
somatostatin
insulin
leptin
neural inhibitors of insulin release
alpha sympathomimetic effect of catecholamines
drug inhibitors of insulin release
diazoxide
phenytoin
vinblastine
colchicine
what lab values should you monitor while a patient is on metformin?
A1C
eGFR
thiazolidinediones effects
increase insulin sensitivity
decrease insulin resistance
increase glucose utilization
pioglitazone has more significant ___________ compared to rosiglitazone
lipid-lowering
mechanism contributing to hypoglycemic effects of thiazolidinediones
increased expression of the glucose transporter GLUT4
increases ability to uptake glucose when stimulated by insulin
Pioglitazone
PPARa and PPARy activity
absorbed in 2 hours
MDD 45mg
food delays uptake
Pioglitazone is metabolized by
CYP2C8 and CYP3A4
rosiglitazone
rapidly absorbed and highly protein bound
once or twice a day
metabolized by CYP2C8 and CYP2C9
rosiglitazone is known to increase ________________ and has no effect on
HDL, LDL, total cholesterol
triglycerides
alpha glucosidase inhibitors MOA
competitively inhibit the intestinal membrane bound alpha glucosidase enzymes
alpha glucosidase inhibits effects
reduce post meal glucose excursions
delay digestion and absorption of starch and dissacharides
alpha glucosidase inhibitors metabolism
NONE!
Digital is eliminated renally unchanged
alpha glucosidase inhibitors are contraindicated in
people with IBD
adverse effects of alpha glucosidase inhibitors
GI disturbance
excess undigested carbs –> increased bacterial digestion of polysaccharides
exenatide
derivative of extendin-4 peptide in Gila monster venom
53% homology with native GLP1
glycine substitution to reduce degradation by DPP4
liraglutide
soluble fatty acid-acylated GLP1 analog
half life - 12 hours
dulaglutide
two GLP-1 analog molecules covalently linked to Fc fragment of human IgG4
protects the GLP1 moiety from inactivation by DPP4
HL - 5 days
albiglutide
human GLP-1 dimer fused to human albumin
half life - 5 days
adverse effect of GLP1 agonists
increase the risk of pancreatitis
GLP1 effects
induces B cell growth
stimulates insulin production
reduces appetite
DPP-4 enzyme
acts on incretin hormones (mainly GLP1 and GIP)
increase insulin secretion and decrease glucagon secretion
half life of GLP1
less than 2 minutes
half life of GIP
7 minutes in healthy people
5 minutes in people with type 2 diabetes
DPP-4 inhibitors mechanism results in
increase circulating GLP-1
increase insulin levels
decrease glucagon levels
metabolism of sitagliptin and linagliptin
excreted unchanged in urine
metabolism of saxagliptin
metabolized by CYP3A4/5
major metabolite is a DPP4 inhibitor
adverse effects of DPP4 inhibitors
GI disturbance
SGLT2 accounts for __________ of glucose reabsorption
90%
inhibition of SGLT2 causes
loss of glucose (glycosuria) and loss of water (osmotic diuresis)
no reabsorption of glucose
how many GLUT transporters are there?
there is now 5!
GLUT5 helps absorb fructose from gut and kidney
what so SGLTs do?
freely filter glucose by the renal glomeruli and reabsorb in the proximal tubules
adverse effects of SGLT2 inhibitors
increased urination
increased UTIs
hypotension
metabolism of SGLT2 inhibitors
glucuronidation in the liver and kidneys by uridine diphosphate glucuronosyltransferase-1A9
amylin is __________________ with insulin from _______________
co-secreted
pancreatic B cell
another name for amilyn
islet amyloid polypeptide
human amylin is unsuitable for ______________ because it ________________
pharmacological use
forms amyloid plaques and fibers (potentially toxic)
MOA of amylin anaolgs
binds to amylin receptor in specific regions of the brain
reduces glucagon release
amylin effects
inhibits glucagon secretion in alpha cells
appetite suppression
delays gastric emptying
handles both endogenous and exogenous
amylin analogs are used for treatment in
Type 1 and 2 DM
insulin allergy
type 1 hypersensitivity
local/systemic urticaria from histamine release by mast cells sensitized by anti-insulin IgE antibodies
immune insulin resistance
lower titer of circulating IgG anti-insulin antibodies that neutralize the action of insulin
associated with other systemic autoimmune disorders like SLE
rapid acting analogs
lispro
aspart
glulisine
inhaled insulin
short acting insulin
human regular
intermediate acting insulin
human NPH
concentrated human regular insulin
U500 human regular insulin
basal analogs
glargine
detemir
degludec
premixed products of insulin
NPH/regular 70/30
Lispro 50/50
Lispro 75/25
Aspart 70/30